Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic

StephenW

<http://cebp.aacrjournals.org/content/early/2011/08/26/1055-9965.EPI-11-0464.abstract>

Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in
chronic hepatitis B and C.

Hitoshi Ikeda1,*,
Ryosuke Tateishi2,
Kenichiro Enooku3,
Haruhiko Yoshida2,
Hayato Nakagawa4,
Ryota Masuzaki5,
Yuji Kondo6,
Tadashi Goto6,
Shuichiro Shiina7,
Yukio Kume8,
Tomoaki Tomiya2,
Yukiko Inoue6,
Takako Nishikawa6,
Natsuko Ohtomo7,
Yasushi Tanoue7,
Tomoko Ono9,
Kazuhiko Koike10, and
Yutaka Yatomi8

+ Author Affiliations

1Department of Clinical Laboratory Medicine, The University of Tokyo

2Department of Gastroenterology, The University of Tokyo

3Department of Gastroenterology, Graduate School of Medicine, the
University of Tokyo

4Department of Gastroenterology, University of Tokyo

5University of Tokyo

6The University of Tokyo

7Gastroenterology, University of Tokyo

8Department of Laboratory Medicine, The University of Tokyo

9Mitsubishi Chemical Medicine Corporation

10Department of Gatroenterology, The University of Tokyo

↵*Corresponding Author:
Hitoshi Ikeda, Department of Clinical Laboratory Medicine, The University
of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
[email protected]

Abstract

Background:
Chronic liver injury evokes a wound healing response promoting
fibrosis and finally hepatocellular carcinoma (HCC), in which hepatic
stellate cells play an important role. Although a blood marker of hepatic
stellate cells is not known, those cells importantly contribute to the
regulation of plasma ADAMTS13 activity, a defect of which causes thrombotic
thrombocytopenic purpura.
Methods:
Plasma ADAMTS13 was evaluated in chronic hepatitis B or C patients with or without HCC.
Results:
Plasma ADAMTS13 activity significantly correlated with serum AST and ALT, liver stiffness value and aspartate aminotransferase-to-platelet ratio index, irrespective
of the presence of HCC, suggesting that it may reflect hepatocellular
damage and subsequent wound healing, and fibrosis as a result of hepatic
stellate cell action. During the three-year follow-up period for patients
without HCC, HCC developed in 10 among 81 patients. Plasma ADAMTS13
activity was significantly higher in patients with HCC development than in
those without, and was a significant risk for HCC development by univariate
and multivariate analyses. Furthermore, during the one-year follow-up
period for patients with HCC treated with radiofrequency ablation, HCC
recurred in 55 among 107 patients. Plasma ADAMTS13 activity or antigen
level was significantly higher in patients with HCC recurrence than in
those without, and was retained as a significant risk for HCC recurrence by
multivariate analysis.
Conclusions:
Higher plasma ADAMTS13 activity and
antigen level was a risk of HCC development in chronic liver disease.
Impact:
Plasma ADAMTS13 as a potential marker of hepatic stellate cells may
be useful in the prediction of hepatocarcinogenesis. Received May 18, 2011.
Revision received August 19, 2011. Accepted August 20, 2011. Copyright ©
2011, American Association for Cancer Research.

StephenW

谷歌翻译
不是100％正确，仅供参考使用.

背景：
慢性肝损伤唤起促进伤口愈合的反应
其中肝纤维化和最后肝细胞癌（HCC）
星状细胞中发挥重要作用。虽然肝血标记
星状细胞是不知道，这些细胞的重要贡献
血浆ADAMTS13活性的调控，其中的缺陷导致血栓
血小板减少性紫癜。
方法：
血浆ADAMTS13在慢性乙型或丙型肝炎患者进行了评估，或肝癌。
结果：
血浆ADAMTS13活性显著相关，与血清AST和ALT，肝刚度值和谷草转氨酶血小板比指数，不论
肝癌的存在，这表明它可能反映肝细胞
损害和随后的伤口愈合，并作为肝纤维化
星状细胞的作用。在后续三年期患者
没有肝癌，肝癌的开发在81例患者中10。血浆ADAMTS13
活动是在患者与肝癌发展显著高于
那些没有和单因素为肝癌发展的显著风险
和多因素分析。此外，一年期间，请按照
期间，肝癌射频消融治疗肝癌患者
在55之间的107例患者复发。血浆ADAMTS13活性或抗原
水平与肝癌复发的患者显着高于
那些没有被保留为肝癌复发的显著风险
多变量分析。
结论：
较高的血浆ADAMTS13活性及
抗原水平在慢性肝病的肝癌发展的风险。
影响：
作为一个潜在的肝星状细胞标记的血浆ADAMTS13可能
在肝癌的预测是有用的。收稿，2011年5月18日。
修订收到，2011年8月19日。接受，2011年8月20日。版权所有©
2011年，美国癌症研究协会。